DGK-δ inhibitors are a class of chemical compounds specifically designed to target and modulate the activity of the enzyme diacylglycerol kinase delta (DGK-δ). DGK-δ is one of the isoforms in the diacylglycerol kinase (DGK) family, enzymes that are critical in lipid signaling pathways. These enzymes catalyze the phosphorylation of diacylglycerol (DAG) to produce phosphatidic acid (PA), both of which are important lipid signaling molecules involved in a variety of cellular processes. DGK-δ plays a significant role in regulating the balance between DAG and PA, which influences key processes such as cell growth, differentiation, and immune responses. Inhibitors of DGK-δ are developed to interfere with its catalytic activity, thereby affecting the downstream signaling pathways that are regulated by the DAG and PA balance.
The development of DGK-δ inhibitors involves a detailed understanding of the enzyme's structure, particularly its active site where the phosphorylation of DAG occurs. Structural biology techniques such as X-ray crystallography, cryo-electron microscopy, and nuclear magnetic resonance (NMR) spectroscopy are used to elucidate the three-dimensional configuration of DGK-δ. This structural information is crucial for identifying the binding sites and catalytic domains that are essential for the enzyme's function. Computational tools, including molecular docking and virtual screening, are employed to identify small molecules that can specifically bind to these sites with high affinity, effectively inhibiting DGK-δ's enzymatic activity. Once potential inhibitors are identified, they are synthesized and subjected to rigorous in vitro testing to evaluate their binding affinity, specificity, and inhibitory potency. These inhibitors are then refined through iterative cycles of chemical optimization to enhance their effectiveness, selectivity, and stability. The study of DGK-δ inhibitors not only provides insights into the specific functions of this enzyme in lipid signaling but also contributes to a broader understanding of the complex regulatory mechanisms that control cellular processes through lipid metabolism and signal transduction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R 59-022 | 93076-89-2 | sc-203227 | 5 mg | $124.00 | 1 | |
Known to inhibit DGK activity and subsequently reduce PA production. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Inhibits protein kinase C (PKC) which affects DAG levels, potentially influencing DGK-δ activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Known protein kinase inhibitor that can affect various DAG-responsive kinases. | ||||||
R-(+)-Etomoxir | 124083-20-1 | sc-208201A sc-208201 | 2 mg 5 mg | $245.00 $430.00 | ||
Inhibits carnitine palmitoyltransferase-1 and may alter lipid signaling dynamics. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that affects downstream lipid signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that can modulate phosphoinositide dynamics. | ||||||
ET-18-OCH3 | 77286-66-9 | sc-201021 sc-201021A sc-201021B sc-201021C sc-201021F | 5 mg 25 mg 50 mg 100 mg 1 g | $111.00 $436.00 $843.00 $1576.00 $3756.00 | 6 | |
An ether lipid that affects various lipid signaling pathways. | ||||||
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $81.00 | 8 | |
Alkylphosphocholine lipid that can disrupt lipid-based signaling. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Influences lipid-mediated pathways, including AKT signaling. | ||||||
Oleic Acid | 112-80-1 | sc-200797C sc-200797 sc-200797A sc-200797B | 1 g 10 g 100 g 250 g | $37.00 $104.00 $580.00 $1196.00 | 10 | |
Unsaturated fatty acid that can influence lipid signaling and membrane dynamics. | ||||||